Renal-Cell Carcinoma

Treatment with the checkpoint inhibitor pembrolizumab (Keytruda) following surgery significantly extended disease-free survival (DFS) in patients with high-risk, clear-cell renal-cell carcinoma (RCC) compared with placebo, according to the results of the KEYNOTE-564 clinical trial. These findings were reported during a plenary session of the American Society of Clinical Oncology (ASCO) 2021 virtual annual meeting. Read More ›




San Francisco, CA—Although there is a biological rationale that supports the “abscopal” effects of radiation therapy plus checkpoint immunotherapy in fighting cancer, this combination showed mixed results and no robust effects in patients with metastatic renal-cell carcinoma (RCC), according to results of 2 preliminary studies presented at the 2020 Genitourinary Cancers Symposium. Read More ›



Subscribe to The Oncology Nurse-APN/PA

To sign up for our newsletter or print publications, enter your contact information below.

I'd like to receive: